GV has led a consortium that included SR One, MRL Ventures, Lundbeckfonden Ventures and Kraft Group in an overubscribed round that closed at $51.7m.
US-based biopharmaceutical company Spero Therapeutics closed an oversubscribed $51.7m series C round on Wednesday led by GV, the early-stage investment vehicle of internet technology conglomerate Alphabet.
Partners Innovation Fund (PIF), SR One, MRL Ventures and Lundbeckfonden Ventures, respective subsidiaries of healthcare system Partners Healthcare and pharmaceutical firms GlaxoSmithKline, Merck & Co and Lundbeck, also contributed to the round, as did diversified conglomerate Kraft Group.
The corporates were joined by venture capital firm Atlas Venture, spinout-focused investment firm Osage University Partners and…